Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citation
Cited by
Items 401–500 of 814
Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy
Sheykhhasan, M., La’ah, A. S., Ahmadieh-Yazdi, A., Yang, P., Tanzadehpanah, H., Mahaki, H., Manoochehri, H., Poondla, N., Kalhor, N., & Al-Musawi, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch002 · Cited by 6
Akhtar, O. S., Szabó, A., Bhatlapenumarthi, V., Forsberg, M., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19700 · Cited by 4
Self-citationA phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith, S. R., Slade, M., Fiala, M. A., Harding, M., Crees, Z. D., Schroeder, M. A., Stockerl-Goldstein, K. E., & Vij, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05975-7 · Cited by 4
Saba, L., Fu, C., Liang, H., & Chaulagain, C. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.006 · Cited by 3
Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma
Marable, M., Kelly, K., Cooperrider, J. H., Jakubowiak, A. J., & Derman, B. A. (2024) · eJHaem · doi:10.1002/jha2.1039 · Cited by 3
Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms
Sperling, A. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014308 · Cited by 3
“3 The presence of t-MNs should be ruled out in any patient undergoing evaluation for persistent or worsening cytopenias.”
BackgroundAdvances in CD19-targeting CAR-T cell therapies for multiple myeloma
Steinhardt, M., Einsele, H., & Waldschmidt, J. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2443093 · Cited by 3
Self-citationMaurer, K., & Jacobson, C. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2460043 · Cited by 5
“…disease [1–3], randomized trials have demonstrated superiority of cAR-t compared to conventional therapy in earlier lines of therapy [8–11], and as such, some cAR-t products are now being moved up to earlier lines of therapy for a subset of higher-risk patients. with many patients…”
Grošelj, U., Kavčič, M., Torkar, A. D., Kafol, J., Lainšček, D., Jerala, R., Sever, M., Zver, S., Serša, G., Čemažar, M., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03828-8 · Cited by 5
“Several encouraging studies show that some groups of patients will benefit from CAR-T cell therapies in the first line setting in the near future [55–59].”
Editorial: T-cell directed therapies in multiple myeloma
Richter, J. R., Anderson, L. D., Ramasamy, K., & Rossi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206475 · Cited by 3
“CARTs such as cilta-cel and ide-cel have shown deep and rapid responses in heavily refractory patients with emerging data from Karmma-3 (15) and Cartitude-4 (16) showing impressive responses in earlier lines, including doubleclass refractory patients.”
Goldsmith, S. R., San-Rozano, M., Katindoy, J., Rattanapichetkul, J., & Rosenzweig, M. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1423959 · Cited by 2
CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
Göker, H., Kelkitli, E., Elifcan, K. A., Demiroğlu, H., Turgut, M., Kambhampati, S., & Krem, M. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1413825 · Cited by 3
“San-Miguel et al. (19) reported the CARTITUDE-4 outcomes of phase 3, a randomized, open-label trial, to compare cilta-cel with the doctor’s choice of one of two SOC regimens: daratumumab-pomalidomide-dexamethasone or pomalidomide-bortezomib-dexamethasone in patients with lenalidomide-refractory MM after one to three l…”
MethodKarp, S., Trautmann‐Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., Bonin, M. V., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06262-9 · Cited by 4
Functional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Ayyappan, S. R., Larsen, J. T., Sanchez, J. F., & Krishnan, A. Y. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.006 · Cited by 2
Advances in NK cell therapy for multiple myeloma
Liu, N., Zeng, Y., Wang, Y., Wang, C., Li, N., & Xu, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101639 · Cited by 3
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 3
“Many challenges limit the therapeutic ef fi cacy of CAR-T cells in hematological malignancies (86, 87, 96, 136 – 146).”
Rosenberg, M. C., Scarpetti, L., Morgan, G. J., & Davies, F. E. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.013 · Cited by 3
Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 9
Self-citationMouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 4
Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma
Luo, K., Zhang, Z., Yao, S., Wang, Y., Amiji, M. M., & Anderson, K. C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114048 · Cited by 4
Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing
Hudecek, M. (2025) · Nature · doi:10.1038/d41586-025-02595-7 · Cited by 2
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 5
Self-citationSun, Z. P., Guo, J., Liu, M., Wang, H., Li, Z., Shen, W., Wang, S., Zhu, H., Liu, X., Li, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103623 · Cited by 4
“25,26 This discrepancy may reflect underreporting of common and expected AEs.”
Rizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
“…dexamethasone (PVd), daratumumab and pomalidomide plus dexamethasone (DaraPd), isatuximab and carfilzomib plus dexamethasone (IsaKd), daratumumab plus carfilzomib and dexamethasone (DaraKd), selinexor and bortezomib plus dexamethasone (SelVd), and cilta-cel (cilta-cabtagene autoleucel) [10–17].”
Self-citationMina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Roy, P. G., Gogia, A., Anwar, Z., Mukherjee, S., & Anwer, F. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00947 · Cited by 2
Casas, P. H. F. D. C. L., Marco, J., Lefkou, E., Soares, T. S., Baghdadi, M. A., Kempaiah, P., Fareed, J., Dreden, P. V., Hungria, V., Marchetti, M., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70356 · Cited by 2
Li, W., & Wang, W. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102670 · Cited by 3
Hashmi, H., Sebastian, T., Rajeeve, S., Farzana, T., Firestone, R., Jurgens, E. M., Miller, K. C., Maura, F., Lesokhin, A. M., Tan, C. R. C., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01494-y · Cited by 5
“Clinical trials like CARTITUDE-4 evaluating the role of CAR T-cell therapy in early relapse (1-2 prior lines of therapy) established that the poor prognostic impact of functionally high-risk disease can be overcome by the use of CAR T in earlier lines of therapy [10].”
Sidana, S., Nagar, S. P., Ghosh, S., et al. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00433-y · Cited by 2
“In clinical trials or case reports related to cilta-cel, non-ICANS NEs, including parkinsonism, cranial nerve palsy, and Guil-lain–Barré syndrome, have been reported, with variable incidence and limited description of timing and presentation [3, 5, 10].”
InfluentialSelf-citationRasche, L., Krauth, M. T., Agis, H., Renner, C., Straßl, I., Teipel, R., Vučinić, V., Weisel, K. C., Willenbacher, W., & Raab, M. S. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02905-1 · Cited by 2
“BT options in earlier LOTs include chemotherapy, immuno-modulatory drugs, PI, mAbs, and targeted agents [7, 9].”
InfluentialSperling, A. S., Derman, B. A., Nikiforow, S., Alonso, A., Ikegawa, S., Orwitz, N., Quinn, D. S., Pearson, D. E., 部德秀, Milanez‐Almeida, P., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx1799 · Cited by 4
ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy
Perales, M., Dietrich, J., Gust, J., Santomasso, B., Rejeski, K., Hansen, D. K., Shah, N. N., Berdeja, J., Bishop, M., Bleickardt, E., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.020 · Cited by 7
Self-citationIelo, C., Fazio, F., Rocchi, S., Rizzello, I., Mancuso, K., Zamagni, E., Cavo, M., & Petrucci, M. T. (2023) · Leukemia Research Reports · doi:10.1016/j.lrr.2023.100399 · Cited by 2
“Due to refractoriness to third-line therapy, the patient was enrolled in the CARTITUDE-4 trial [5] and randomized to receive CAR T-cell therapy in December 2021.”
MethodSelf-citationDisparity in hematological malignancies: From patients to health care professionals
Chen, X., Shukla, M., & Fleur-Lominy, S. S. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101169 · Cited by 3
Ferreri, C. J. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.01.058 · Cited by 3
Eichenauer, D. A., Heger, J., Kruschel, I., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19434 · Cited by 2
Cohen, I., Vaxman, I., & Gertz, M. A. (2024) · Acta Haematologica · doi:10.1159/000539225 · Cited by 6
“The Role of ASCT in the Era of Immunotherapy Chimeric antigen receptor (CAR) T-cell therapy and bispeci fi c T-cell engagers (BiTEs) were demonstrated to be very effective in the relapse/refractory setting in MM [51 – 54].”
Schütt, J., Brinkert, K., Plis, A., Schenk, T., & Brioli, A. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.39 · Cited by 3
van Voss, M. R. H., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M. E. M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2397436 · Cited by 5
“…that is needed for CAR T-cell manufacturing (median time from leukapheresis to CAR-T cell infusion was 44–49 days in the aforementioned KaRMMa-3 and CARTITUDE-4 studies) [95,96], which can be problematic for patients with rapidly progressive disease without effective options for bridging therapy.”
Self-citationPopova, M. O., & Витальевич, М. В. (2024) · Oncohematology · doi:10.17650/1818-8346-2024-19-3-185-198 · Cited by 3
How can we improve the successful identification of patients suitable for CAR-T cell therapy?
Feng, Y., Wu, L., Gu, T., Hu, Y., & Huang, H. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2399152 · Cited by 2
“…(NCT04181827) trial recently revealed that cilta-cel significantly improved the PFS in patients with MM refractory to lenalidomide who had previously received one to three treatments compared to the standard therapy (76% vs. 49%, p 0.001), thereby lowering the risk of disease recurrence [77].”
InfluentialYu, X., Liu, C., Hu, S.-Z., Yuan, Z.-Y., Ni, H.-Y., Sun, S., Hu, C., & Zhan, H.-Q. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03774-0 · Cited by 2
“After reviewing the abstracts, 3633 studies were eliminated, and 28 studies were eligible after a thorough assessment of the full text, and finally, five articles were included [13–17] in our meta-analysis.”
Katodritou, E., Kastritis, E., Dalampira, D., Fotiou, D., Theodorakakou, F., Delimpasi, S., Spanoudakis, E., Ntanasis‐Stathopoulos, I., Papadopoulou, T., Sevastoudi, A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.002 · Cited by 2
Chari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 4
Self-citationAnticancer drug therapy for anaplastic thyroid cancer
Kiyota, N., Koyama, T., & Sugitani, I. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0287 · Cited by 6
“This treatment has demonstrated high ef fi cacy and gained approval for hematological malignancies (75, 76, 77).”
Morgese, P., Majors, S., & Patel, D. V. (2025) · Journal of Market Access & Health Policy · doi:10.3390/jmahp13020014 · Cited by 4
Updates to Management of Multiple Myeloma
Callander, N. S., Mangan, P. A., & Kumar, S. K. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.5008 · Cited by 4
Sierro-Martínez, B., Guijarro-Albaladejo, B., Fernández-Cisnal, R., Rodríguez‐Gil, A., Hernández-Díaz, P., de la Rosa-Garrido, M., Carrasco-Brocal, I., Lara‐Chica, M., Gómez, V. E., Muñoz-García, R., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06899-0 · Cited by 2
Park, H., Robinson, J., Flanagan, C., Pawlyn, C., Jackson, G. H., & Jones, J. R. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2560085 · Cited by 3
“…patients), respectively. the median follow-up period ranged from 8.5 to 65.4 months. whilst the cARtitUDe-4 and KarMMa-3 trials reported on the efficacy of cilta-cel and ide-cel, respectively, against the standard of care (SOc), the studies were insufficiently powered for meta-analysis [21,26].”
InfluentialProgressive Multiple Cranial Neuropathies as a Manifestation of CAR-T Neurotoxicity
Lazzari, Z. T., Gandh, A. S., Sannananja, B., et al. (2025) · The Neurohospitalist · doi:10.1177/19418744251393076 · Cited by 2
Yi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
Rodríguez‐Otero, P., Tamariz‐Amador, L., & Miguel, J. F. S. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00278-8 · Cited by 2
Self-citationQu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?
Bay, J., Auberger, B., Bouleuc, C., Cohen, R., Delom, F., Firmin, N., Gandemer, V., L’Allemain, G., Magné, N., de Nonneville, A. T., et al. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.12.003 · Cited by 2
Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in June 2023
Ilić, D., & Liović, M. (2023) · Regenerative Medicine · doi:10.2217/rme-2023-0152 · Cited by 2
Neugut, A. I., & Bates, S. E. (2023) · The Oncologist · doi:10.1093/oncolo/oyad222 · Cited by 2
Maura, F., Freeman, C. L. L., Maclachlan, K. H., Larráyoz, M., Ziccheddu, B., Meermeier, E. W., Garcés, J., Durante, M. A., Lee, H., Firestone, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.08.692978 · Cited by 4
Slade, M., Fiala, M. A., Kirchmeyer, M., King, J., Gao, F., Schroeder, M. A., Stewart, A. K., Stockerl-Goldstein, K. E., Chen, C. I., & Vij, R. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.014 · Cited by 1
Shrinking the divide: improving myeloma CART access
Nooka, A. K., Hartley-Brown, M. A., Anderson, K. C., & Lonial, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011659 · Cited by 2
“As the CARTs are incorporated into earlier lines of therapy, 13,14 the question of inclusivity becomes increasingly important, and this study provides the necessary guidance.”
BackgroundDhakal, B. (2024) · The Hematologist · doi:10.1182/hem.v21.3.202432 · Cited by 1
Self-citationBarberio, J., Lash, T. L., Nooka, A. K., Naimi, A. I., Patzer, R. E., & Kim, C. (2024) · Acta Haematologica · doi:10.1159/000539127 · Cited by 1
“…regimens for later treatment lines that have potential for signi fi cant myelosuppression (e.g., bis-peci fi c antibodies [32, 33] and chimeric antigen receptor therapies [34, 35]) or from being included in future clinical trials due to eligibility criteria related to neutropenia thresholds.”
Immunotherapy in multiple myeloma
Cantó, P. A., Herraiz, M. A., & Comos, J. D. L. R. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.05.003 · Cited by 3
Brieghel, C., Petersen, S. L., Brown, P. D. N., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.286002 · Cited by 1
Ho, P. J., & Li, E. W. (2025) · Internal Medicine Journal · doi:10.1111/imj.16647 · Cited by 2
“In CARTITUDE-4, patients received cilta-cel following a median of two prior lines, the incidence was 4% 16 and 6% in the KarMMa-3 trial with a median of three prior lines.”
Self-citationRetrospective Analysis: S100 as Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome
Schulenburg, A., Rüsing, L. Z., Bumberger, A. M., et al. (2025) · Oncology · doi:10.1159/000543949 · Cited by 1
“Recently, chimeric antigen receptor (CAR) T-cell therapy has gained widespread application for hematologic diseases like lymphoma, leukemia, and myeloma [1 – 3].”
McCurdy, A. B. R., Gul, E., Reece, D. E., Chu, M. P., Jimenez-Zepeda, V. H., Louzada, M., Song, K., Mian, H. S., Sébag, M., White, D. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.02.011 · Cited by 2
Fang, Y., Lin, W., Shen, L., Ni, B., Zhang, M., Cai, Y., Zhou, Y., & Hou, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564774 · Cited by 1
Cellular Therapies: From a Theoretical Concept to an Immuno-augmented Reality
Cherukuri, P., Khan, A. N., Gera, K., Karulkar, A., Asija, S., Banik, A., & Purwar, R. (2025) · Springer eBooks · doi:10.1007/978-3-031-81787-8_4 · Cited by 1
Self-citationNew therapeutic options and trends in the treatment of multiple myelom
Hájek, R., Muroňová, L., Mihályová, J., Horňáková, M., Popková, T., Plonková, H., & Jelínek, T. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.031 · Cited by 1
Mohyuddin, G. R., & Goodman, A. M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01034-w · Cited by 1
A great mitigator of non-ICANS neurotoxicities?
Mahdi, J. (2025) · Blood · doi:10.1182/blood.2025029233 · Cited by 1
Cardiovascular complications of cellular immunotherapies and associated risk factors
Grunblatt, E., & Akhter, N. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00057-7 · Cited by 1
“TheincidenceoftheseCVAEs TheincidenceoftheseCVAEs washighlyvariableacrossdifferenttrials,withratesofarrhythmiaranging from4to38% 5,10,11,13,14,18 – 22 .”
Advances in chimeric antigen receptor-T therapies to target tumor resistance in B-cell malignancies
Salem, N., & Hamieh, M. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000892 · Cited by 1
Chimeric antigen receptor T-cell therapy for multiple myeloma
Liu, L., & Htut, M. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001167 · Cited by 1
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
“Idiosyncratic toxicities more frequent with certain CAR-T products such as cilta-cel have also been reported, including the delayed onset of neurocognitive events (tremors, psychomotor retardation, inattention, micrographia) [95,96].”
Sebastian, T. M., Rajeeve, S., Farzana, T., Firestone, R., Jurgens, E. M., Miller, K., Costa, B. A., Lesokhin, A. M., Tan, C. R. C., Shah, G. L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01343-4 · Cited by 2
“…safety seen in pivotal clinical trials, two B cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T-cell products, idecabtagene vicleucel (ide-cel) [3] and ciltacabtagene autoleucel (cilta-cel) [4], have now been approved for use in RRMM after only 1 – 2 prior lines of therapy.”
T cell redirecting therapy for relapsed multiple myeloma
Tan, M. S. Y., Hellou, T., & Dingli, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03432-z · Cited by 3
“CARTITUDE-4 assessed cilta-cel vs. SOC in lenalidomide-refractory patients with 1–3 prior therapies, demonstrating superior PFS (NR vs. 11.8 months; HR, 0.26), response depth, and MRD negativity rates compared to standard of care [38] (Table 2).”
InfluentialKawamura, K., Tsukada, N., Kimura, S., Kako, S., Minakata, D., Enami, T., Hamano, Y., Yamamoto, G., Ota, S., Obara, N., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70129 · Cited by 1
“T cells, have emerged for triple‐class exposed relapsed/refractory patients, demonstrating superior results compared to conventional treatments [17–22].”
Bird, S., & Pawlyn, C. (2025) · Nature · doi:10.1038/d41586-025-02592-w · Cited by 1
Richardson, T., Tharmaseelan, H., Kobbe, G., Baermann, B., Holderried, T. A. W., Schmitz, F., Crysandt, M. M., Gödel, P., Wolfensberger, N., Schütte, D., et al. (2025) · eJHaem · doi:10.1002/jha2.70139 · Cited by 2
“…of chimeric antigen receptor T-cell (CAR-T) therapy targeting the B-cell maturation antigen (BCMA) has opened new possibilities for patients with RRMM. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are currently approved options with others in development [1, 2].”
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 2
Gavriatopoulou, M., Manganas, S., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.004 · Cited by 1
Jenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2
Designing a strong bridge to CAR-T cells with bispecifics
Gay, F., & D’Agostino, M. (2025) · Blood · doi:10.1182/blood.2025030525 · Cited by 1
Kamboj, I., Habib, A., Chang, D., Rashid, A., Vegel, A. J., Graf, K., Struble, E., Mushtaq, M. U., Mahmoudjafari, Z., Green, K., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.09.015 · Cited by 5
Self-citationIdentification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 2
“[123] Cilta-cel has been extensively investigated in clinical settings, with its applications evolving from monotherapy to combination regimens and across an increasingly broad range of disease stages.”
Guadagno, L., Schütt, J., Brinkert, K., Schenk, T., & Brioli, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2575438 · Cited by 3
Banerjee, R. K., Simon, S., Voutsinas, J. M., Wu, Q. V., Gausman, D., Dizon, J., Xie, E., Yeung, C. C. S., Lin, M., Lynch, R. C., et al. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100022 · Cited by 1
Suzuki, T., & Iida, S. (2025) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.25038 · Cited by 2
“14 Among SPMs, myeloid malignancies—including myelodysplastic syndrome and acute myeloid leukemia— were observed in 1.3% and 0% of patients in the KarMMa-3 trial and 1.4% and 0% in the CARTITUDE-4 trial (CAR T vs. SOC group, respectively), 13,14 indicating that such events remain relatively…”
InfluentialPillai, A. A., Tiwari, M., Patil, S. B., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.71571 · Cited by 1
How to approach the high-risk myeloma from induction through relapse?
Weisel, K. C., Schaefers, C., & Leypoldt, L. B. (2025) · Hematology · doi:10.1182/hematology.2025000762 · Cited by 1
Pasvolsky, O., Marcoux, C., Milton, D. R., Haider, A. A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Smallbone, P., Lin, P., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02771-3 · Cited by 3
Soto, T. D., Moukalled, N. M., & Mohty, M. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02782-0 · Cited by 2
Gustine, J. N., Scaringi, J. A., Bauer, F., Cirstea, D. D., Branagan, A. R., Puliafito, B. R., Maus, M. V., Frigault, M. J., Yee, A. J., Mahmood, U., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02819-9 · Cited by 4
“Treatment with BCMA CAR-T in MM patients is characterized by rapid response kinetics, with a median time to fi rst response and complete response (CR) of 1 and 3 months, respectively [1 – 5].”
InfluentialPiron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 8
Self-citationTrends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection
Pickl, J. F., & Oberbauer, R. W. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag011 · Cited by 1
Ren, Y., Lin, Z., Li, S., Zhang, R., Lai, Z., Jiang, H., Qu, Z., Huo, G., Zhang, D., Yang, Y., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1721114 · Cited by 2
Tailored strategies for improved control of CAR-T cells in multiple myeloma
Bielowski, A., Kilian, T., Vera-Cruz, S., Deveuve, Q., Kraus, S., Einsele, H., Hudecek, M., & Danhof, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1740345 · Cited by 1
Self-citationLopez-Munoz, N., Bar, N., Diels, J., Sanden, S. V., Mendes, J. V., Lee, S., Hernando, T., Lendvai, N. K., Patel, N., Ishida, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-025-03479-y · Cited by 1
“This approval is based on data from the CARTITUDE‑1 and CARTITUDE‑4 stud‑ ies [14, 15].”
InfluentialSelf-citation
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.